Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10229)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
TAFAZZIN
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
NADPH oxidase 4 (NOX4) [Driver]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Target for Ferroptosis | Driver | ||||
Responsed Disease | Hereditary Leiomyomatosis | ICD-11: 2C90 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Hippo signaling pathway | hsa04390 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
RCC4 cells | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0498 | |
786-O cells | Renal cell carcinoma | Homo sapiens | CVCL_1051 | ||
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
MDA-MB-231 cells | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | ||
In Vivo Model |
One million 786O cells with or without shTAZ were implanted subcutaneously into the healthy 8-week-old JAX NOD.CB17-PrkdcSCID-J mice; both male and female mice were used. Once tumor volume reached 120 mm3, mice were randomized into control or erastin treatment group. The vehicle (ORA-plus) or erastin (0.1 ml of 4 mg/ml erastin) was administrated by oral gavage twice daily for 20 days.
Click to Show/Hide
|
||||
Response regulation | Cell density-regulated ferroptosis is mediated by TAZ through the regulation of EMP1-NOX4, suggesting its therapeutic potential for renal cell carcinoma (RCC) and other TAZ-activated tumors. | ||||
Cystine/glutamate transporter (SLC7A11) [Driver; Suppressor]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [2] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Hippo signaling pathway | hsa04390 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | |
SNU-398 cells | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0077 | ||
HT-1080 cells | Fibrosarcoma | Homo sapiens | CVCL_0317 | ||
Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 | ||
HLE cells | Hepatocellular carcinoma | Homo sapiens | CVCL_1281 | ||
Hep 3B2.1-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0326 | ||
In Vivo Model |
SNU398-parental cells, SNU398-shLuc, or SNU398-shYAP/TAZ cells (106 in 100 ul PBS) were implanted into the left flanks of immunodeficient NOD/SCID; common receptor-/-(NSG) mice. When tumors were palpable, Sorafenib (LC Laboratories, S-8502) was applied at 20 mg/kg daily via gavage, SSA (Sulfasalazine, Sigma, S0883) was given at 120 mg/kg daily by intraperitoneal injection, 20 mM BSO (Lbuthionine-sulfoximine, Sigma, B2515) was given in the drinking water for 3 weeks.
Click to Show/Hide
|
||||
Response regulation | In a TEAD-dependent manner, YAP/TAZ induce the expression of SLC7A11, a key transporter maintaining intracellular glutathione homeostasis, thus enabling hepatocellular carcinoma cells to overcome Sorafenib-induced ferroptosis. At the same time, YAP/TAZ sustain the protein stability, nuclear localization, and transcriptional activity of ATF4 which in turn cooperates to induce SLC7A11 expression. | ||||
Hepatocellular carcinoma [ICD-11: 2C12]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [2] | ||||
Target Regulator | Tafazzin (TAFAZZIN) | Protein coding | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Hippo signaling pathway | hsa04390 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | |
SNU-398 cells | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0077 | ||
HT-1080 cells | Fibrosarcoma | Homo sapiens | CVCL_0317 | ||
Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 | ||
HLE cells | Hepatocellular carcinoma | Homo sapiens | CVCL_1281 | ||
Hep 3B2.1-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0326 | ||
In Vivo Model |
SNU398-parental cells, SNU398-shLuc, or SNU398-shYAP/TAZ cells (106 in 100 ul PBS) were implanted into the left flanks of immunodeficient NOD/SCID; common receptor-/-(NSG) mice. When tumors were palpable, Sorafenib (LC Laboratories, S-8502) was applied at 20 mg/kg daily via gavage, SSA (Sulfasalazine, Sigma, S0883) was given at 120 mg/kg daily by intraperitoneal injection, 20 mM BSO (Lbuthionine-sulfoximine, Sigma, B2515) was given in the drinking water for 3 weeks.
Click to Show/Hide
|
||||
Response regulation | In a TEAD-dependent manner, YAP/TAZ induce the expression of SLC7A11, a key transporter maintaining intracellular glutathione homeostasis, thus enabling hepatocellular carcinoma cells to overcome Sorafenib-induced ferroptosis. At the same time, YAP/TAZ sustain the protein stability, nuclear localization, and transcriptional activity of ATF4 which in turn cooperates to induce SLC7A11 expression. | ||||
Hereditary Leiomyomatosis [ICD-11: 2C90]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | ||||
Target Regulator | Tafazzin (TAFAZZIN) | Protein coding | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Hippo signaling pathway | hsa04390 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
RCC4 cells | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0498 | |
786-O cells | Renal cell carcinoma | Homo sapiens | CVCL_1051 | ||
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
MDA-MB-231 cells | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | ||
In Vivo Model |
One million 786O cells with or without shTAZ were implanted subcutaneously into the healthy 8-week-old JAX NOD.CB17-PrkdcSCID-J mice; both male and female mice were used. Once tumor volume reached 120 mm3, mice were randomized into control or erastin treatment group. The vehicle (ORA-plus) or erastin (0.1 ml of 4 mg/ml erastin) was administrated by oral gavage twice daily for 20 days.
Click to Show/Hide
|
||||
Response regulation | Cell density-regulated ferroptosis is mediated by TAZ through the regulation of EMP1-NOX4, suggesting its therapeutic potential for renal cell carcinoma (RCC) and other TAZ-activated tumors. | ||||
References